Literature DB >> 27586383

Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity.

Xin Chen1, Joost J Oppenheim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27586383     DOI： 10.1038/nrrheum.2016.145

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  What have we learnt from targeted anti-TNF therapy?

Authors:  M Feldmann; R O Williams; E Paleolog
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

2.  Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Ryoko Hamano; Jeffrey J Subleski; Arthur A Hurwitz; O M Zack Howard; Joost J Oppenheim
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

3.  Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.

Authors:  Hak-Ling Ma; Lee Napierata; Nancy Stedman; Stephen Benoit; Mary Collins; Cheryl Nickerson-Nutter; Deborah A Young
Journal:  Arthritis Rheum       Date:  2010-02

Review 4.  anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.

Authors:  A Armuzzi; P Lionetti; C Blandizzi; R Caporali; S Chimenti; L Cimino; P Gionchetti; G Girolomoni; G Lapadula; A Marchesoni; A Marcellusi; F S Mennini; C Salvarani; R Cimaz
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Jan-Mar       Impact factor: 3.219

5.  Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.

Authors:  Xin Chen; Monika Bäumel; Daniela N Männel; O M Zack Howard; Joost J Oppenheim
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

6.  Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis.

Authors:  Fiona E McCann; Dany P Perocheau; Gerhard Ruspi; Katrina Blazek; Marie L Davies; Marc Feldmann; Jonathan L E Dean; A Allart Stoop; Richard O Williams
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

Review 7.  Etanercept: a review of its use in autoimmune inflammatory diseases.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 8.  Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

Authors:  Petra Votavova; Jakub Tomala; Marek Kovar
Journal:  Immunol Lett       Date:  2014-02-07       Impact factor: 3.685

9.  Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.

Authors:  Dao Xuan Nguyen; Michael R Ehrenstein
Journal:  J Exp Med       Date:  2016-06-06       Impact factor: 14.307

10.  Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.

Authors:  Michael R Ehrenstein; Jamie G Evans; Animesh Singh; Samantha Moore; Gary Warnes; David A Isenberg; Claudia Mauri
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307
  10 in total
  9 in total

Review 1.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

Review 2.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

3.  TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4+Foxp3+ Regulatory T Cells: Implications in the Treatment of Autoimmune Diseases and Cancer.

Authors:  Md Sahidul Islam; Yang Yang; Xin Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Cytokine       Date:  2017-04-25       Impact factor: 3.861

Review 5.  Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.

Authors:  Ping Li; Ying Zheng; Xin Chen
Journal:  Front Pharmacol       Date:  2017-07-12       Impact factor: 5.810

Review 6.  The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment.

Authors:  Yifei Wang; Jingbin Zheng; Md Sahidul Islam; Yang Yang; Yuanjia Hu; Xin Chen
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

Review 7.  TNFR2: Role in Cancer Immunology and Immunotherapy.

Authors:  Yang Yang; Md Sahidul Islam; Yuanjia Hu; Xin Chen
Journal:  Immunotargets Ther       Date:  2021-04-21

Review 8.  Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.

Authors:  Huimin Zou; Ruixin Li; Hao Hu; Yuanjia Hu; Xin Chen
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

9.  TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders.

Authors:  Faraz Shaikh; Jiang He; Pratiti Bhadra; Xin Chen; Shirley W I Siu
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.